Document Detail


Long-term follow-up of adalimumab monotherapy for rheumatoid arthritis in Japanese patients: a report of six cases.
MedLine Citation:
PMID:  21243493     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We present six cases of patients with Japanese rheumatoid arthritis (RA) treated with a tumor necrosis factor (TNF)-alpha blocking agent, adalimumab as monotherapy for 220 weeks. All six patients were women, and the median age was 54.0 ± 7.07 years old. The median duration of the disease was 7.43 ± 11.1 years, and the median disease activity score (DAS28-CRP) was 5.35 ± 0.69. Three of six patients were able to continue to receive this treatment for 220 weeks successfully, and the DAS28-CRP decreased to 1.89 ± 0.75. Two patients withdrew because of lack of efficacy, and one patient withdrew because of adverse events (non-Hodgkin lymphoma). Adalimumab resulted in a sustained clinical response in RA patients during 220-week follow-up.
Authors:
Kunihiro Ichinose; Tomoki Origuchi; Shin-ya Kawashiri; Naoki Iwamoto; Keita Fujikawa; Toshiyuki Aramaki; Makoto Kamachi; Kazuhiko Arima; Mami Tamai; Hideki Nakamura; Hiroaki Ida; Atsushi Kawakami; Katsumi Eguchi
Related Documents :
67283 - 1-deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of...
2013973 - Elevated thrombin-antithrombin iii complex concentrations in patients with gynaecologic...
7223933 - Lower gastrointestinal bleeding. diagnostic approach and management conclusions.
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-01-18
Journal Detail:
Title:  Rheumatology international     Volume:  32     ISSN:  1437-160X     ISO Abbreviation:  Rheumatol. Int.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-24     Completed Date:  2012-10-15     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8206885     Medline TA:  Rheumatol Int     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  483-7     Citation Subset:  IM    
Affiliation:
Department of Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. kunizo1234abcd@yahoo.co.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Monoclonal, Humanized / administration & dosage*,  adverse effects
Antirheumatic Agents / administration & dosage*,  adverse effects
Arthritis, Rheumatoid / drug therapy*,  pathology,  radiography
Female
Follow-Up Studies
Humans
Long-Term Care
Middle Aged
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*,  physiology
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/Tumor Necrosis Factor-alpha; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis.
Next Document:  The association between dermatomyositis and papillary thyroid cancer: a case report.